On May 11, 2021 (ASX:PTX) reported a new research program with the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne to advance its CAR-T programs utilising the OmniCAR platform (Press release, Prescient Therapeutics, MAY 11, 2021, View Source;utm_medium=rss&utm_campaign=prescient-signs-car-t-agreement-with-peter-mac-cancer-centre [SID1234580141]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new program builds on the company’s existing research agreement with Peter Mac focusing on cell therapy enhancement programs.

The new agreement expands this relationship to include the development of the OmniCAR platform.

The company said it is developing three OmniCAR programs internally, including next-generation CAR-T therapies for acute myeloid leukaemia (AML), Her2+ solid tumours and glioblastoma multiforme (GBM).

Prescient said it is developing OmniCAR as a CAR-T platform, capable of being deployed by other CAR-T and oncology companies under licence to advance their own programs.

Under the terms of the new agreement, Prescient will have access to the expertise and facilities of Peter Mac, led by international CAR-T expert, Professor Phil Darcy, to undertake part of the OmniCAR preclinical development programs.

Prescient will own any resulting intellectual property from the work.

The company’s partnership with Peter Mac also now includes two post-doctoral scientists and two research assistants who are dedicated full time to Prescient work. Prescient has also secured grant funding of $100,000 from the federal government’s Innovation Connections scheme towards this research.